In the high-dose group of ENGAGE-AF TIMI study, a dose halving resulted in a decrease in plasma concentration of the edoxaban by approximately 29% and a reduction in average anti–factor Xa activity by 25% [23]. This evidence concerns the gene F10 and atrial fibrillation.